Elevance HealthELV
About: Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of December 2024. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
Employees: 104,200
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1.23% more ownership
Funds ownership: 87.52% [Q3] → 88.75% (+1.23%) [Q4]
9% more call options, than puts
Call options by funds: $677M | Put options by funds: $619M
6% less funds holding
Funds holding: 1,665 [Q3] → 1,561 (-104) [Q4]
25% less first-time investments, than exits
New positions opened: 209 | Existing positions closed: 277
26% less funds holding in top 10
Funds holding in top 10: 50 [Q3] → 37 (-13) [Q4]
28% less capital invested
Capital invested by funds: $105B [Q3] → $75.9B (-$29B) [Q4]
36% less repeat investments, than reductions
Existing positions increased: 460 | Existing positions reduced: 722
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
RBC Capital Ben Hendrix 35% 1-year accuracy 25 / 71 met price target | 14%upside $478 | Outperform Reiterated | 23 Apr 2025 |
Guggenheim Jason Cassorla 14% 1-year accuracy 2 / 14 met price target | 23%upside $518 | Buy Reiterated | 23 Apr 2025 |
Cantor Fitzgerald Sarah James 28% 1-year accuracy 28 / 99 met price target | 15%upside $485 | Overweight Reiterated | 23 Apr 2025 |
Barclays Andrew Mok 37% 1-year accuracy 22 / 60 met price target | 24%upside $522 | Overweight Maintained | 23 Apr 2025 |
Baird Michael Ha 39% 1-year accuracy 9 / 23 met price target | 26%upside $529 | Neutral Downgraded | 15 Apr 2025 |
Financial journalist opinion
Based on 23 articles about ELV published over the past 30 days
